Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6296-6305

  Chan, Wing Keung ^a   Sutherland, May Kung ^c   Li, Ying ^a   Zalevsky, Jonathan ^d,e   Schell, Sarah ^a   Leung, Wing ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c SEATTLE GENETICS INC   (United States)

^d Xencor Inc   (United States)

^e Takeda San Diego Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; CELL ADHESION MOLECULE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; LEUKEMIA ANTIGEN; LINTUZUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; DEGRANULATION; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; HLA-B ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; MICE; MICE, INBRED NOD; MICE, SCID; MYELOID-LYMPHOID LEUKEMIA PROTEIN; RECEPTORS, IGG; RECEPTORS, KIR; TRANSLOCATION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869222692     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0668     Document Type: Article

References (20)

1. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R III, Patel Y, Harden A, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A 1991;88:10735-9. (Pubitemid 21915912)
2. Harper DP, Aplan PD. Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects. Cancer Res 2008;68:10024-7.
3. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-33. (Pubitemid 350006257)
4. Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood 2009;113:6061-8.
5. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-33.
6. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002;359:1909-15. (Pubitemid 34615770)
7. Pui CH. Acute leukemias with the t(4;11)(q21;q23). Leuk Lymphoma 1992;7:173-9.
8. Woodard P, Barfield R, Hale G, Horwitz E, Leung W, Ribeiro R, et al. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer 2006;47:931-5. (Pubitemid 44656117)
9. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2008;115:1204 - 13.
10. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008;68:8049- 57.
11. Ra fiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JC. XmAb-5574 antibody demonstrates superior antibody dependent cellular cytotoxicity as compared to CD52 and CD20 targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia 2012;26:1720-2.
12. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005;23:4110-6. (Pubitemid 46211316)
13. Sutherland MK, Yu C, Anderson M, Zeng W, van Rooijen N, Sievers EL, et al. 5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. Mabs. 2010 Jul 30;2(4). [Epub ahead of print].
14. Sutherland MK, Yu C, Lewis TS, Miyamoto JB, Morris-Tilden CA, Jonas M, et al. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs 2009;1:481-90.
15. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol 2011;155:14-29.
16. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acutemyeloid leukemia. J Clin Oncol 2010;28:955-9.
17. Bari R, Leung M, Turner VE, Embrey C, Rooney B, Holladay M, et al. Molecular determinant-based typing of KIR alleles and KIR ligands. Clin Immunol 2011;138:274-81.
18. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fcg RIIIa-158 V/V and V/F polymorphism. Blood 2007;110:2561-4. (Pubitemid 47523179)
19. Asano H, Yamamoto G, Hosoi M, Takahashi T, Hangaishi A, Kurokawa M. Complete molecular remission in refractory acute myeloid leukemia with MLL /AF9 treated with gemtuzumab ozogamicin. Leuk Res 2010;34:e152-3.
20. Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009;114:2667-77.